The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
Exploring the companies and themes that make up this emerging and exciting new sector
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
Cybin's latest R&D initiative (CYB004) is a proprietary molecule targeting anxiety disorders.
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine announces a new program to incorporate AI "machine learning" into its drug R&D.
Bright Minds Biosciences Announces Application to List on Nasdaq
Bright Minds Biosciences has applied to uplist to the NASDAQ.
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound
Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.
Atai To Upsize IPO Financing To $246 Million, The Industry Leader Just Got Bigger
Atai Life Sciences has re-filed with the SEC to increase its IPO financing from $100 to $246 million. It's a big deal.
‘I’m a lighter me’: Can Mike Tyson and psychedelics help boxers with brain trauma?
The former heavyweight champion says psychedelics would have helped him with his mental health during his career. Some scientists and companies agree
Getting People to Help Changes Everything: William Cook, CEO of MindLeap
Mydecine Innovations Group is a psychedelics company that The Dales Report has been watching closely this past year.
MindMed’s New CEO Well-Prepared For Next Stage of Corporate Development
Co-Founder JR Rahn has stepped down as CEO of MindMed. His replacement, Robert Barrow, brings a wealth of clinical trials experience.
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy